ArticleCancer research2021
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancer.Genome medicine · 2026Article
- Exploring Schiff Bases Derived from 2-hydroxybenzaldehyde as Potential Anticancer Agents: Synthesis, Characterization, Molecular Docking and in-vitro Evaluation.Cell biochemistry and biophysics · 2025Article
- Review
- Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer.NPJ breast cancer · 2025Article
- Machine learning and gene network integration reveal prognostic subnetworks and biomarkers in pancreatic cancer.Computational and structural biotechnology journal · 2025Article
- Changes in the molecular nodes of the Notch and NRF2 pathways in cervical cancer tissues from the precursor stages to invasive carcinoma.Oncology letters · 2024Article
- Nucleosome reorganisation in breast cancer tissues.Clinical epigenetics · 2024Article
- Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.Signal transduction and targeted therapy · 2023Review
- Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy.BMC genomic data · 2022Article
- KDM6A Depletion in Breast Epithelial Cells Leads to Reduced Sensitivity to Anticancer Agents and Increased TGFβ Activity.Molecular cancer research : MCR · 2022Article
- CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal.The EMBO journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 10 institutions in 4 countries.
Barrie PeckThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Philip Bland *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Ioanna Mavrommati *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Gareth Muirhead *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Hannah CottomThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Patty T WaiThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Sarah L MaguireThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0001-6654-3620
Holly E BarkerThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0002-9350-5520
Eamonn MorrisonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Divya KriplaniThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Lu YuDivision of Cancer Biology, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0001-8378-9112
Amy GibsonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Giulia FalgariThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Keith BrennanFaculty of Life Sciences, University of Manchester, Manchester, England, United Kingdom.
Gillian FarnieSGC Oxford, University of Oxford, Oxford, England, United Kingdom.
Richard BuusThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0002-3386-3465
Rebecca MarlowThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Daniela NovoThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Eleanor KnightThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Naomi GuppyThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0003-1004-3605
Daniela KolarevicThe Royal Marsden NHS Foundation Trust, London, England, United Kingdom.ORCID https://orcid.org/0000-0003-3450-6344
Snezana SusnjarDepartment of Medical Oncology, The Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
Natasa Medic MilijicDepartment of Pathology and Cytology, The Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
Kalnisha NaidooThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0002-9253-619X
Patrycja GazinskaThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Ioannis RoxanisThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Sunil PancholiThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0002-0880-1588
Lesley-Ann MartinThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Erle M HolgersenThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Maggie C U CheangClinical Trials and Statistics Unit, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0001-5718-2501
Farzana NoorThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Sophie Postel-VinayDepartment of Drug Development (DITEP), Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.ORCID https://orcid.org/0000-0001-5562-1857
Gerard QuinnCentre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
Simon McDadeCentre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.ORCID https://orcid.org/0000-0002-3024-4773
Lukas KrasnyDivision of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom.ORCID https://orcid.org/0000-0003-3447-846X
Paul HuangDivision of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom.
Frances DaleyThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Fredrik WallbergThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Jyoti S ChoudharyDivision of Cancer Biology, The Institute of Cancer Research, London, England, United Kingdom.
Syed HaiderThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Andrew N TuttThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.
Rachael NatrajanThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom. rachael.natrajan@icr.ac.uk.ORCID https://orcid.org/0000-0002-9987-2946
Breast Cancer Now · GBInstitute of Cancer Research · GBQueen's University Belfast · GBOncology Institute of Vojvodina · RSCancer Research UK · GBInserm · FRRoyal Marsden NHS Foundation Trust · GBUniversity of Manchester · GBUniversity of Oxford · GBWalter and Eliza Hall Institute of Medical Research · AU
Funding
Breast Cancer Now 2017JULYPCC005Breast Cancer Now BREAST CANCER NOW RESEARCH CENTRECancer Research UK 25351Medical Research Council MC_PC_18051
Abstract
Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies for this hard-to-treat patient population, yet studies using high-throughput and accurate models to define the functions of driver genes in TNBC to date have been limited. Here, we employed unbiased functional genomics screening of the 200 most frequently mutated genes in breast cancer, using spheroid cultures to model
Indexed as
AnimalsCarcinogenesisCell ProliferationCells, CulturedCREB-Binding ProteinDrug Screening Assays, AntitumorFemaleGenomicsHCT116 CellsHEK293 CellsHumansMiceMice, Inbred NODMice, NudeMolecular Targeted TherapyMutationCREB-Binding ProteinCREBBP protein, humanProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.